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Summary.-Fibrinogen radioiodinated by the iodine monochloride method was
tested as a tumour radiodiagnostic agent in mice. The *I-fibrinogen cleared from
the blood of tumour-bearing mice more rapidly than from that of normal mice, but
it cleared from the whole body more slowly, suggesting it accumulated in a sub-
stantial tumour-related compartment in the abnormal mice. The tumour concentra-
tion steadily increased for 4 h after injection, at which time it reached a peak concen-
tration of 11.4% of the injected dose/g. This concentration was higher than the
peak concentration for Ga-citrate (not reached until 24 h) or any other oncophilic
radiopharmaceutical tested in this tumour model. The early accumulation is
consistent with the use of 1231 as a tracer label for fibrinogen. A combination of the
large tumour concentration of *I-fibrinogen, an increased catabolic rate induced by
chemical modification, and the exceptional nuclear properties of 1231 for scintigraphic
imaging, could lead to a very useful radiodiagnostic procedure for cancer.
INDEPENDENT observations by both
Day, Planinsek and Pressman (1959) and
by Spar, Goodland and Bale (1959)
showed that 1311-fibrinogen (rat) was
selectively concentrated by some trans-
plantable rat tumours. Similar results
were found in dogs with spontaneous
tumours (Spar et al., 1960). These results
led several investigators to attempt to
localize human neoplasms by scintigraphy
using human 1311-fibrinogen (Monasterio,
Becchini and Riccioni, 1964; Hisada et al.,
1968; Riccioni, 1969). All these investi-
gations demonstrated positive localization
in some tumour types within 6-24 h
after injection. However, the poor
nuclear decay properties of 1311 have
blunted enthusiasm for labelled fibrinogen
as a radiodiagnostic imaging agent.
The ready availability of labelling-
graderadionuclidically pure 1231 (DeNardo
et at., 1976) led us to prepare 1231-fibrino-
gen for thrombus scintigraphy (DeNardo
et at., 1975) and to examine fibrinogen
localization in tumours as another poten-
tial application for 1231-fibrinogen.
Our animal investigations involved
spontaneous canine tumours (Wortman
et al., 1976) and chemically induced
tumours in monkeys, as well as rodent
models. Although rodent-tumour biology
may be different from human-tumour
biology, these models proved useful in
comparing various radiopharmaceutical
preparations and in testing the correlation
of fibrinogen localization with thrombo-
genic and fibrinolytic properties of neo-
plasms.
This article reports the preparation of
highly purified human *I-fibrinogen, its
in vitro characterization, organ distribu-
tion and blood plasma clearance kinetics
in adult BALB/c mice with transplanted
KHJJ tumours (Rockwell, Kallman and
Fajardo, 1972). A number of investiga-
tors have reported the metabolism and
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distribution of labelled fibrinogen in
rabbits, dogs and humans, and have
employed sophisticated compartmental
modelling to determine transcapillary and
catabolic rate parameters (Franks et al.,
1976; Schultz and Heremans, 1966).
Reports of the catabolic T1/2 of human
fibrinogen in rats (Campbell et al., 1956;
Mutschler, 1964) suggest that the rate is
much faster than in larger mammals.
However, we are unaware of a definitive
study of the blood and organ distribution
kinetics of *I-fibrinogen in mice.
MATERIALS AND METHODS
The fibrinogen used in these studies was
prepared under sterile and pyrogen-free
conditions from healthy human donor plasma.
The plasma was collected in citrate anti-
coagulant and centrifuged in bags at 4TC
for 50 min to remove red blood cells. The
Blomback 1-2 fraction wras prepared under
sterile conditions by successive ethanol/salt
fractionation, as previously described by
Blombaek and Blomback (1956) and Welch,
and Krohn (1975). The purified fibrinogen
precipitate was dissolved in a citrate buffer
(pH 6-35, 0-055 M citrate+40g/l dextrose)
and divided into 1-ml aliquots containing
about 10 mg of fibrinogen. These aliquots
w%Aere quick-frozen using dry ice and ethanol
and stored at -70°C for future use.
The fibrinogen preparation was tested for
its clotting properties by the spectro-
photometric assay of Regoeczi (1967) and
was analysed by Sepharose-4B gel filtration
chromatography (Krohn, Sherman andWelch,
1972) and by polyacrylamide-gel column
electrophoresis (7.500 acrylamide), with
sodium dodecyl sulphate (SDS) and with and
without mercaptoethanol.
The fibrinogen was radioiodinated by the
iodine monochloride method (McFarlane,
1963; Welch and Krohn, 1975). The desired
volume ofradioactivity (high-sp.-act. iodina-
tion-grade Na*I in 01N NaGH) was added to
10 mg of fibrinogen, followed by 50 ul of
0-0033M ICI prepared in our laboratory by
the method of McFarlane (1963). The
resulting product had an average of about
two iodine atoms per protein molecule. The
product of the radioiodination reaction was
purified on a (0.9 x 20)m column of Sepha-
dex G-25-80 eluted with a neutral buffer
(0-05M NaCitrate, 015M NaCl). The radio-
chemical purity of the resulting *I-fibirinogen
preparation was routinely tested by cellulose
acetate electrophoresis (300 V, 4 ma, 8 min)
and by precipitation with trichloroacetic
acid (3 mg protein, 10% TCA w/v). The
isotopic clottability of the *I-fibrinogen was
evaluated by standard methods (Welch and
Krohn, 1975).
Pieces of KHJJ adenocarcinoma were
implanted by s.c trocar injection into the
flank of adult BALB/c mice weighing 20-
25 g (Rockwell et al., 1972). After 14 days,
the tumour weighed -0 7 g and was not
grossly necrotic. At this time, about 10 XCi
of *I-fibrinogen (,1 uCi/,ug) in 100 1ul was
injected into a dorsal tail vein. The total
amount of radiopharmaceutical injected into
each mouse was measured by w%Aeighing the
syringe before and after injection. A weighed
standard was also prepared and diluted into a
50-ml volume.
Mice were counted in a standard geometry
equidistant from two Nal(Tl) scintillation
crystals at selected times after injection, to
measure the whole-body retention of *I-
fibrinogen, and 50 1l blood samples were
drawn from the tail several times before
killing. The mice were killed at 1, 4, 8, 24,
or 48 h after injection and samples of blood
and flank muscle, as well as the entire lungs,
liver, brain, stomach, kidneys, spleen and
tumour were excised, weighed wet and
counted in a well-type Nal(Tl) scintillation
crystal. A 1-ml aliquot of the standard was
counted in the same well geometry so that
absolute tissue concentrations could be
expressed as a percentage of the injected dose
per gram of wet tissue (%ID/g). The tissues
were dabbed dry but were not perfused or
washed. The tails were counted, and any
mouse with more than 10% of the injected
dose in the tail was excluded from the study.
In order to minimize the effect of bio-
logical and radiopharmaceutical variability,
we chose the following protocol: *I-fibrinogen
from a single labelling was tested in groups
of mice at several time intervals after
injection, and the mean 00 injected dose/g for
each organ was calculated; three different
batches of *I-fibrinogen were prepared and
each preparation was used to study a group
of 3 mice each at 4, 8 and 24 h; 2 of the
preparations were also studied at 1 and 48 h.
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ments were done on healthy BALB/C mice
of equivalent sex, age, and weight.
The slopes (0 693/T1/2) and intercepts of
blood clearance curves were calculated by a
least-squares linear regression analysis of
ln(activity) vs time (Coleman et al., 1974).
RESULTS
The *I-fibrinogen prepared by the
methods described above was chemically
and fuinctionally indistinguishable in vitro
from authentic fibrinogen, and had pro-
perties similar to those of radioiodinated
human fibrinogen as given in the litera-
ture. The spectrophotometric clottability
of the fibrinogen preparation averaged
95±2% before iodination and 94±3°O/
afterwards. The radioisotopic clott-
ability averaged 93±1%0, and the TCA
precipitability of the purified preparation
for injection was always >99%. The
Sepharose-4B chromatograms of freshly
separated fibrinogen and of IC0-labelled
fibrinogen are shown for comparison in
Fig. 1, along with the elution volumes of
lyophilizedE. coli (void volumeVv) and *1-
iodide (bed volume Vb). There was no
detectable difference between the chroma-
tographic elution profiles of the iodinated
fibrinogen and the original fibrinogen.
Similarly, polyacrylamide-gel column elec-
trophoresis of our fibrinogen detected no
impurities (Fig. 2). The migration
pattern agreed with that reported in the
literature (Mosesson et al., 1967).
The blood and whole-body clearance
of *I-fibrinogen is shown in Fig. 3 for
healthy and tumour-bearing mice. The
blood catabolic half-times were 29-8±2-2 h
and 284± 1*9 h for healthy and tumour-
bearing mice, respectively. About half
the *I-fibrinogen was cleared with these
half-times; the remainder was cleared
rapidly from the blood into extravascular
spaces.
To test whether the tumour altered the
distribution of *I-fibrinogen, the fractional
extravascular space was calculated for
individual animals at each sampling time
by calculating %ID (total body) minus
%ID (total blood) divided by %ID (total
body). The %I1D (total blood) was esti-
mated by multiplying the measured
%ID/g of blood by a blood volume
assumed to be 7.50 of the animal's
weight.
Fig. 4 shows that both healthy and
tumour-bearing mice reached steady-state
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-Fi. I. Sepharose-4B gel chromatograms for fibrinogen. The column effluient was monitored for
optical density (O.D.) at 280 nm and for ra(dioactivity (ct/min). Column was 1-5 x 58 cm and was
eluted with a neutral buffer (0 05 M NaCitrate, 0-1.5 M NaCI, 0-02 M r-aminocaproic acid). VV = 31
ml, Vb 101 ml, Kd O 50 for fibrinogeni.
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FIG. 3. Clearance of *I-fibi.inogen from the
whole bo(ty and bloocd of normal (0) and
ttumour-bearing (0) mice. Error bars
represent s.d. (n>6 per point).
ratios of intravascular-extravascular
radioisotope distribution within 24 h. The
extravascular space of the normal mice
contained 52±4% of the radioactivity
remaining in the animal; whereas, for the
tumour-bearing mice, 68+3% was in the
extravascular space. If the intercept of
the slow phase of the blood clearance
curve represents, as frequently suggested,
the intravascular distribution of labelled
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FIG. 2.-Polyacrylamide SDS gel electro-
phoresis of fibrinogen. MIercaptoethanol
was added to the left handi column to cause
fibrinogen to unwind to the constituent a,
f and y chains, which migrated half way
down the column. No lower-mol.-wt
impurities were detected by this analysis.
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FIG. 4. Fractional extravascular volume of
normal (0) and tumour-bearing (0) mice
at selected times after injection. Error
bars represent ±s.d. (n:=3 per point).
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FeICe. 5.-Pharmacokinetics of *I-fibrinogen
in the organs of mice bearing KHJJ
tumouts. Each circle represents a mean for
, mice anc( the lines coinnect the means of
the several means.
proteins (Schultze and Heremans, 1966),
an alternative method for calculating
extravascular space is the complement of
that intercept. The calculated intercepts
were 44±4% and 34±5% for normal
and tumour-bearing mice, respectively.
The extravascular spaces calculated in
this way were, therefore, 56±4% for
normals, and 66±5%o for KHJJ mice.
The two different analyses led to the same
estimate of extravascular space for normal
mice (52+4% v8 56±4%), and for
tumour-bearing mice (68+2 v8 66±5%),
but there was a discrepancy between
normal and tumour-bearing mice which
will receive comment in the discussion.
The organ distribution kinetics for *I-
fibrinogeni are shown in Figs. 5 and 6.
Each data point represents a mean for 3
mice, and the error bars represent the
range of means. At 48 h, a single mean
and range are given for 6 mice. Most
remarkably, the curves for lung, liver,
kidneys, and brain clearance all closely
parallel the blood curve. The muscle
curve parallels blood concentration after
4 h, but shows some accumulation during
the first few hours after injection. The
only curves that are qualitatively different
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FIG. 6. Pharmacokinetics of *I-fibrinogen ill
the organs of mice bearing KHJJ tumours.
Each circle represents a meais foi 3 miceand
the lines coInect the means of the
several means.
are those for tumour, spleen and stomach.
Tumour concentration showed an early
accumulation phase, with a maximum
concentration at 4 h that averaged 2*5±
0 3x that at I h. The clearance from
the tumour from 4 to 24 h after injec-
tion had a calculated half-life of over
3 days, or about 4x the blood clearance
half-life in tumour-bearing mice. During
the second day after injection, the tumour
concentration curve became indistinguish-
able from that for blood.
DISCUSSION
Our research goals include investiga-
tion of the potential usefulness of 123J-
fibrinogen for tumour radiodiagnosis. W;re
therefore developed a standard labelling
method, and carefully characterized our
*I-fibrinogen preparation. The clot-
tability, gel electrophoresis and gel per-
meation chromatography results are
similar to many of those reported in the
literature for *I-fibrinogen preparations of
good quality. The most critical test of
the biological integrity of tagged fibrino-
gen, however, is its in vivo behaviour.
Biosynthetic 14C-fibrinogen behaved in
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vivo identically to 1311-fibrinogen in both
rats (Campbell et al., 1956) and rabbits
(Cohen et al., 1955). The fibrinogen
catabolic half-lives reported in the litera-
ture are 3 3±0f3 (humans), 2 6+0 3
(rabbits), 2-4±0-2 (dogs) and 1P2±0 1
(rats) days. Our result of 1-2+0-1 days
in healthy mice is consistent with these
results, and suggests that the mice are not
reacting to this single injection of a
heterologous (human) fibrinogen prepara-
tion in any wav that alters its catabolic
rate.
The range of catabolic half-lives
reported for fibrinogen in any one species
is large. Early measurements of long
catabolic half-lives probably reflected con-
tamination by other proteins with slower
catabolic rates than that of fibrinogen.
Unusually fast catabolic rates for some
fibrinogen preparations reflected altera-
tions to the fibrinogen molecule, either by
the separation technique or by radio-
isotope labelling (Coleman et al., 1974).
This investigation did not compare
various methods of iodination, but was
based on earlier results with the ICI
method (Krohn et al., 1972). This method
yielded a product which proved satis-
factory, and the techniques were relatively
simple to perform. The fibrinogen pre-
pared from the blood of carefully selected
human donors has now been labelled and
used safely in more than 100 patients
(DeNardo et al., 1975). We have there-
fore adopted the procedure described
here for preparation of *I-fibrinogen for
routine clinical use.
The blood clearance and whole-body
retention curves for *I-fibrinogen were
different for tumour-bearing and healthv
mice. The presence of tumour was associ-
ated with increased clearance of tracer
from the blood, but decreased excretion
from the body, suggesting an additional
extravascular compartment which ac-
cumulated *I-fibrinogen. This conclusion
is independent of the assumed blood
volume, which is only a scaling factor for
Fig. 3. The blood clearance curves for
normal and tumour-bearing mice were
inseparable during the first few hours after
injection, but the total intravascular
volumes, calculated as the intercept from
regression analysis extrapolation of the
24-48-h data, were different. One of the
mechanisms that has been postulated for
the accumulation of tracer proteins within
tumours involves increased tumour capil-
lary permeability. If the different dis-
tribution rates for KHJJ and healthy
mice were a result of this mechanism, the
fractionalintravascularvolumes calculated
in this way should be different. Because
they were the same early on but diverged
later, the physical mechanism of increased
interstitial space within neoplasms appears
insufficient as a complete explanation
for *I-fibrinogen accumulation within
tumours; however, its role cannot be
completely dismissed.
We can estimate the relative size of the
added compartment accumulating *I-
fibrinogen in the tumour-bearing mice.
From Fig. 4, their intravascular space
contained 32±3%o of the remaining *I-
fibrinogen at 24-48 h, and from the
extrapolated zero-time blood concentra-
tion, for the normal animals, we can
estimate that the equilibrated extra-
vascular space was 1*260* 15x the
intravascular space. This implies that
40± 6°o ofthe *I-fibrinogen was in normal
equilibrated extravascular fluid space
during this time period and leaves the
remaining 28+7% of the *I-fibrinogen in
a tumour-associated extravascular space.
The *I-fibrinogen within the tumour at
24 and 48 h accounted for only 14±4%o
ofthe *I-fibrinogen present at those times,
so that *I-fibrinogen must be collecting in
some other extravascular space. Two
organs containing large concentrations of
radioiodine at 24-48 h were the stomach
and spleen (Fig. 6) both known repositories
of degraded fibrinogen. Because the
KHJJ tumour contains fibrinolytic
enzymes, we postulate that radioactivity
in these organs at 24-48 h is the same
tracer that was in the tumour earlier. In
effect, the stomach and spleen represent
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originally collected in the tumour. After
degradation by tumour lytic enzymes, the
resulting degradation products of *I-
fibrinogen accumulate in the stomach and
spleen before their ultimate excretion. The
radioactivity in the stomach is most
likely *I-iodide from deiodination, a
process inevitable with iodinated radio-
pharmaceuticals. Further investigations
are under way to model this mechanism
mathematically in order to test its
validity.
The observation that the organ-
distribution kinetic curves for lung, liver,
muscle, kidneys and brain all paralleled
the blood-clearance curve convinces us
that these organ concentrations reflect
primarily the blood pool. If *I-fibrino-
gen were damaged initially it would
accumulate in the liver and cause an early
rise in that organ's concentration (Cole-
man et al., 1974). Therefore, the absence
of accumulation in the liver further
reflects the good quality of the radio-
pharmaceutical. Lung and brain did not
accumulate *I-fibrinogen despite the
thrombogenic factors within these tissues
(Wortman et al., 1976).
The most remarkable accumulation of
radioactivity occurred in cancerous tissue,
which contained 2-5x as much activity
at 4 h as at 1 h after injection. This
concentration decreased by 10% during
the first day, while the blood concentration
was decreasing by 75%. That *I-fibrino-
gen was not washed out of the tumour by
the concentration gradient with blood
indicates that the radioactivity was
trapped in an insoluble form within the
tumour and was not in a simple equili-
brium with interstitial space.
In comparison with other proposed
oncophilic radiopharmaceuticals, the
11.4% ID/g tumour for *I-fibrinogen
completely overshadows the maximum
concentration within this same tumour
model of 2 6±0-3% ID/g for isotopically
labelled bleomycin, a chemotherapeutic
antibiotic with some radiodiagnostic
potential (Krohn et al., 1977). It is
about equal to the highest 67Ga-citrate
concentration measured in the KHJJ
model (10.5% ID/g) but that value was
not achieved until 24 h after injection.
In summary, *I-fibrinogen accuniu-
lates in a large tumour-related compart-
ment in KHJJ-tumour-bearing mice. The
concentration peaks within a few hours
after injection and at a level higher than
any other oncophilic radiopharmaceutical
tested in this animal model. The early
accumulation is eminently compatible
with the use of 123I, an ideal short-lived
nuclide for gamma-camera imaging of
tumours. The slow blood clearance of
*I-fibrinogen is, however, a disadvantage
because it contributes to the low tumour/
blood ratio. McFarlane (1963) found
that over-iodination of fibrinogen
increased its catabolic rate, and others
exploited this finding by deliberately over-
iodinating fibrinogen, with which they
were able to achieve higher clot/blood
ratios in thrombus scintigraphy (Harwig
et al., 1975). We are now testing the
potential of over-iodinated 123I-fibrinogen
as an oncophilic radiodiagnostic agent.
The combination of high tumour concen-
tration and increased biological clearance,
plus the exceptional physical decay pro-
perties of 1231, could lead to a very useful
radiodiagnostic procedure for cancer.
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